A new study suggests that two experimental weight-loss drugs could potentially produce greater reductions in body weight than Mounjaro, although neither treatment is currently approved for routine medical use in the UK.
The research found that people taking tirzepatide, the active ingredient in Mounjaro, lost an average of about 19% of their body weight over roughly 17 months. By comparison, participants receiving the experimental drug retatrutide lost 22.1% over about 48 weeks.
Experimental Drugs Show Promising Results
Another experimental injection, amycretin, was associated with an average weight reduction of around 23.9% over 36 weeks, according to the research.
The study also compared the findings with semaglutide-based injections, including Wegovy and Ozempic. Participants using these treatments could lose around 18% of their body weight over a comparable period, according to the reported results.
Further Research and Approval Needed
Researchers say the findings from the experimental treatments are encouraging, but the results do not mean the drugs are ready for widespread clinical use.
Retatrutide has not yet received approval for medical use from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Experts say further research and regulatory review will be required before such experimental treatments can become broadly available.